Article
Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
Acta gastro-enterologica Belgica - 1 Jan 2000
Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E
Abstract excerpt
Patients with metastatic colorectal cancer and KRAS mutation are unlikely to benefit from treatment with anti-EGFR antibodies, and testing for KRAS mutation in this setting is recommended. Pathologists have a crucial role in accurate testing for KRAS mutations, whether or not testing is performed in their own laboratory, as mutation analysis is performed on paraffin embedded tissue selected by the pathologists....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.